摘要
目的 探讨宫颈鳞癌中程序性死亡配体1(PD-L1)表达情况及22C3、SP263、E1L3N3种抗体免疫组化染色的一致性.方法 收集解放军总医院两个医学中心89例复发或转移性宫颈鳞癌样本,用PD-L1 3种克隆号抗体22C3、SP263、E1L3N进行染色,并采用联合阳性评分(CPS)、肿瘤细胞比例评分(TPS)两种评分标准,在不同阈值下对抗体的一致性进行统计学分析.结果 宫颈鳞癌在CPS阳性阈值为1时,PD-L1阳性率从高到低依次为22C3(98.31％)、E1L3N(97.75％)、SP263(93.90％);CPS 为 10 时,阳性率依次为 E1L3N(76.40％)、22C3(72.88％)、SP263(69.51％);TPS 阈值为 1％时,阳性率依次为 E1L3N(95.51％)、22C3(93.22％)、SP263(92.68％);TPS 为10％时,阳性率依次 E1L3N(65.17％)、22C3(64.41％)、SP263(60.98％).当 CPS 为 1 或 10 时、TPS 为 1％或 10％时,E1L3N 与 22C3、SP263 与 22C3、SP263 与 E1L3N 均表现较好的一致性(Kappa=0.66～0.98).无论使用 CPS 或TPS,组内相关系数检验显示3个克隆号抗体判读数据有高度一致性(ICC分别为0.987、0.984).结论 E1L3N、SP263与22C3之间具有较高的可互换性,为临床检测PD-L1在宫颈癌组织中的表达情况,提供了更多选择.
Abstract
Objective To investigate the expression of PD-L1 in the cervical squamous cell carcinomas and the consistency of IHC detection of three different antibodies,including 22C3,SP263,and E1L3N.Methods The samples of 89 patients with recurrent or metastatic cervical squamous cell carcinoma were collected from PLA General Hospital.The samples were respectively stained with 22C3,SP263 and E1L3N,and combined positive score(CPS)and tumor cell proportion score(TPS)were used.The consistency of antibodies was statistically analyzed at different thresholds.Results When the positive threshold of CPS≥ 1,the positive rate of PD-L1 was 22C3(98.31％),E1L3N(97.75％)and SP263(93.90％).When CPS ≥10,the positive rates were E1L3N(76.40％),22C3(72.88％)and SP263(69.51％).When the TPS threshold ≥1％,the positive rates were E1L3N(95.51％),22C3(93.22％)and SP263(92.68％).When TPS ≥10％,the positive rates were E1L3N(65.17％),22C3(64.41％)and SP263(60.98％).When CPS ≥ 1 or 10,and TPS≥1％or 10％,E1L3N and 22C3,SP263 and 22C3,and SP263 and E1L3N showed good consistency(Kappa=0.66-0.98).Whether CPS or TPS was used,intra-class correlation coefficient tests showed a high degree of agreement among the three antibodies(ICC 0.987,0.984,respectively).Conclusion The three antibodies,E1L3N,SP263,and 22C3,can be used interchangeably,offering greater selectivity for clinical testing requirements.
NETL
NSTL
万方数据